Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M. Schürrle SB, et al. Among authors: beauregard jm. Eur J Nucl Med Mol Imaging. 2024 Mar 26. doi: 10.1007/s00259-024-06682-1. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38528164
Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy.
Mansouri Z, Salimi Y, Akhavanallaf A, Shiri I, Teixeira EPA, Hou X, Beauregard JM, Rahmim A, Zaidi H. Mansouri Z, et al. Among authors: beauregard jm. Eur J Nucl Med Mol Imaging. 2024 May;51(6):1516-1529. doi: 10.1007/s00259-024-06618-9. Epub 2024 Jan 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38267686 Free PMC article.
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ. Wild D, et al. Among authors: beauregard jm. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):183-195. doi: 10.1007/s00259-023-06383-1. Epub 2023 Sep 18. Eur J Nucl Med Mol Imaging. 2023. PMID: 37721581 Free PMC article. Clinical Trial.
Pregnancy-Related Deaths by Hispanic Origin, United States, 2009-2018.
Parker-Collins W, Njie F, Goodman DA, Cox S, Chang J, Petersen EE, Beauregard JL. Parker-Collins W, et al. Among authors: beauregard jl. J Womens Health (Larchmt). 2023 Dec;32(12):1320-1327. doi: 10.1089/jwh.2023.0057. Epub 2023 Sep 6. J Womens Health (Larchmt). 2023. PMID: 37672570 Free PMC article.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Among authors: beauregard jm. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Clinical Trial.
144 results